SKYE — Skye Bioscience Cashflow Statement
0.000.00%
- $224.82m
- $145.28m
- 37
- 21
- 89
- 47
Annual cashflow statement for Skye Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 1.05 | -6.56 | -8.52 | -19.5 | -37.6 |
Depreciation | |||||
Non-Cash Items | -7.38 | 0.411 | 1.37 | 7.38 | 24 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.296 | 0.094 | 0.647 | -0.762 | -0.469 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -6.03 | -6.05 | -6.47 | -12.7 | -14 |
Capital Expenditures | 0 | -0.007 | -0.091 | -0.095 | -0.013 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | 5.31 | 6.61 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Cash from Investing Activities | 0 | -0.007 | -0.091 | 5.21 | 6.6 |
Financing Cash Flow Items | — | — | — | — | -0.006 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 6 | 6.7 | 13.1 | -0.209 | 16.4 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.023 | 0.639 | 6.51 | -7.74 | 9.09 |